(株)免疫生物研究所の貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|---|---|---|
| 東証GRT | 医薬品 | 4570/E00986 | Immuno-Biological Laboratories Co.,Ltd. |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|---|---|---|---|---|---|---|---|---|
| 2013/05/17 | 日証協 | 18,740株 | -2.85% | 4,880株 | -37.6% | 17,666株 | +20.29% | 3,391株 | -52.17% |
| 2013/05/10 | 日証協 | 19,290株 | +13.2% | 7,820株 | +113.66% | 14,686株 | +5.91% | 7,090株 | +1717.95% |
| 2013/05/02 | 日証協 | 17,040株 | -15.05% | 3,660株 | +838.46% | 13,866株 | -16.19% | 390株 | -84.95% |
| 2013/04/26 | 日証協 | 20,060株 | -7.81% | 390株 | -90.8% | 16,544株 | -5.27% | 2,592株 | -33.02% |
| 2013/04/19 | 日証協 | 21,760株 | +14.77% | 4,240株 | -10.17% | 17,465株 | +7.92% | 3,870株 | +31.14% |
| 2013/04/12 | 日証協 | 18,960株 | +10.81% | 4,720株 | +114.55% | 16,184株 | +8.15% | 2,951株 | +28.25% |
| 2013/04/05 | 日証協 | 17,110株 | +2.46% | 2,200株 | 0% | 14,964株 | +12.26% | 2,301株 | +94.34% |
| 2013/03/29 | 日証協 | 16,700株 | +56.66% | 0株 | -100% | 13,330株 | +71.71% | 1,184株 | -18.96% |
| 2013/03/22 | 日証協 | 10,660株 | -39.67% | 5,930株 | +62.02% | 7,763株 | -46.94% | 1,461株 | -60.52% |
| 2013/03/15 | 日証協 | 17,670株 | +22.79% | 3,660株 | +82.09% | 14,631株 | +19.51% | 3,701株 | +26.49% |
| 2013/03/08 | 日証協 | 14,390株 | +66.36% | 2,010株 | -83.25% | 12,242株 | +22.52% | 2,926株 | -63.38% |
| 2013/03/01 | 日証協 | 8,650株 | +98.85% | 12,000株 | +3143.24% | 9,992株 | +41.11% | 7,991株 | +862.77% |
| 2013/02/22 | 日証協 | 4,350株 | +3.57% | 370株 | 0% | 7,081株 | -3.28% | 830株 | +388.24% |
| 2013/02/15 | 日証協 | 4,200株 | -2.33% | 0株 | 0% | 7,321株 | -7.22% | 170株 | -84.11% |
| 2013/02/08 | 日証協 | 4,300株 | -3.15% | 0株 | -100% | 7,891株 | -4.48% | 1,070株 | -45.13% |
| 2013/02/01 | 日証協 | 4,440株 | -34.12% | 320株 | +60% | 8,261株 | -15.45% | 1,950株 | +0.52% |
| 2013/01/25 | 日証協 | 6,740株 | +1.51% | 200株 | -95.28% | 9,771株 | +12.95% | 1,940株 | -32.4% |
| 2013/01/18 | 日証協 | 6,640株 | +50.91% | 4,240株 | +6% | 8,651株 | +7.72% | 2,870株 | -9.75% |
| 2013/01/11 | 日証協 | 4,400株 | +51.72% | 4,000株 | 0% | 8,031株 | +11.99% | 3,180株 | +7850% |
※株式分割は考慮していませんのでご注意ください。